Arcutis Biotherapeutics (ARQT) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, gaining 148.5% versus a loss of 10.6%. Over five years, XERS leads with a +682.0% price change compared with +58.1% for ARQT. Arcutis Biotherapeutics is the larger company by market cap ($3.33 billion vs $3.10 billion), about 1.1 times the size.
On valuation, Arcutis Biotherapeutics trades at a lower forward P/E (24.1x vs 63.6x for Xeris Biopharma). Xeris Biopharma converts more of its revenue into profit, with a net margin of 0.2% versus -4.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARQT | XERS |
|---|---|---|
| Share price | $26.36 | $16.97 |
| Market cap | $3.33B | $3.10B |
| 1-day change | -2.98% | +2.11% |
| YTD return | -9.23% | +116.18% |
| 1-year return | -10.61% | +148.46% |
| 5-year return | +58.13% | +682.03% |
| P/E ratio (TTM) | 119.82 | — |
| Forward P/E | 24.09 | 63.64 |
| EPS (TTM) | $0.22 | $-0.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $376.07M | $291.85M |
| Revenue growth (YoY) | +91.34% | +43.72% |
| Net income (latest FY) | $-16.14M | $554.00K |
| Gross margin | 90.24% | 85.41% |
| Operating margin | -3.25% | 8.53% |
| Net margin | -4.29% | 0.19% |
| 52-week high | $34.80 | $17.28 |
| 52-week low | $19.30 | $5.25 |
| Distance from 52-week high | -24.25% | -1.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +53.19% | +1.89% |
| Average volume | 2.58M | 2.86M |
| Shares outstanding | 126.46M | 182.70M |
| Employees | 354 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XERS has outperformed ARQT by 159.1 percentage points over the past year.
- Arcutis Biotherapeutics grew revenue faster in its latest fiscal year (+91.34% vs +43.72%).
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
ARQT vs XERS FAQ
Which is bigger, Arcutis Biotherapeutics or Xeris Biopharma?
Arcutis Biotherapeutics (ARQT) is larger, with a market capitalization of $3.33B compared with $3.10B for Xeris Biopharma (XERS).
Which stock has performed better over the past year, ARQT or XERS?
XERS returned +148.46% over the past 12 months, compared with -10.61% for ARQT (price return, excluding dividends). Past performance does not predict future results.
Are Arcutis Biotherapeutics and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.